AcademicLabs Becomes International Sponsor to MABA to Bolster Scientific Due Diligence Across Life Sciences Industry
Read article below:
“And just like that, he’s gone”
For fans of the movie The Usual Suspects, that line captured what it was like to wake up to the investment reality of 2022.
2020 and 2021 were banner years for companies going public any way they could, including SPACs, which skyrocketed in popularity in 2020 but had fallen back to earth by the end of last year. These exits provided returns to their investors, which resulted in more and new investors who went on to raise new and larger funds.
And now all this new money was looking for more and more investment opportunities, to which [ Read more… ]
Posted: December 24, 2021
Dear Sidecar Fund Investors,
We hope that everyone remains healthy and is doing well.
As we near the Fund’s second anniversary, the Fund has made six investments so far, several were in companies that were new to us, and several were in existing MABA portfolio companies, and there is room left for just one more large investment, before the Fund is fully invested.
The pandemic has affected a significant drop in applications in the first half of 2021, with numbers recovering somewhat, beginning in September. This resulted in a much smaller than usual amount of companies entering diligence, with, [ Read more… ]
New View Surgical – novel VisionPort™ System is the first surgeon-controlled, multi-camera laparoscopic visualization system.
Posted: September 9, 2021
We hope everyone is staying healthy and safe.
We are happy to announce that the Sidecar Fund has made an investment in New View Surgical (http://newviewsurg.com/), whose novel VisionPort™ System is the first surgeon-controlled, multi-camera laparoscopic visualization system.
New View Surgical (NVS) is a MABA portfolio company, which received multiple investments from our group, the first being in 2017, and included our first internal investment Pool, along with multiple investors. NVS has made steady progress over the years, securing FDA Clearance for its VisionPort™ System in June of this year. The current investment is part of a [ Read more… ]
Posted June 11, 2021
Dear Sidecar Fund I investors,
We hope that everyone is healthy (and vaccinated) and doing well.
Our portfolio companies continue to execute on their plans and their regular reports are being updated to this site, as they are received. I hope you are as happy to read of some of the progress being reported as we are. Also, I recently reached out to all of our portfolio company CEOs for an in-person update on their activities, which you can read in the attached Dashboard.
The general market is beginning to see a rebound, as Covid-19 cases decline, and restrictions [ Read more… ]
Novel neuroprotective therapeutics for the treatment of stroke, traumatic brain injury (TBI), concussion, and neurodegenerative diseases.
Developing a pipeline of best-in-class oncolytic immunotherapeutics that are highly effective in treating cancer patients with solid cancers.